{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:11:42Z","timestamp":1780791102286,"version":"3.54.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Background<\/jats:title>\n Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors are novel drugs widely used in clinical practice for the treatment of dyslipidemia. However, real-world data regarding their long-term neurological safety and tolerability in large populations remain incomplete. Therefore, we utilized the FAERS and real-world data from Chinese patients to jointly analyze the association between PCSK9 inhibitors and adverse drug events (ADEs) related to nervous system disorders.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n A disproportionality analysis was performed on all ADEs associated with PCSK9 inhibitors in the FAERS database from the third quarter of 2015 to the second quarter of 2025. The reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) methods were employed to comprehensively evaluate and screen for statistically significant positive signals of adverse drug reactions related to nervous system disorders. These signals were further validated using follow-up data from 1,203 Chinese coronary heart disease (CHD) patients treated with PCSK9 inhibitors.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 173,622 reports involving at least one PCSK9 inhibitor were identified in FAERS. Statistically significant positive ADEs signals associated with PCSK9 inhibitors included: Memory Impairment [\n n<\/jats:italic>\n \u202f=\u202f1,346, ROR\u202f=\u202f1.48 (95% CI 1.4\u20131.56), IC\u202f=\u202f0.55 (IC025 0.47), Bonferroni-\n p<\/jats:italic>\n =\u202f2.2028e\n \u221242<\/jats:sup>\n ], Amnesia [\n n<\/jats:italic>\n \u202f=\u202f452, ROR\u202f=\u202f1.25 (95% CI 1.14\u20131.38), IC\u202f=\u202f0.32 (IC025 0.18), Bonferroni-\n p<\/jats:italic>\n \u202f=\u202f0.0097], Head Discomfort [\n n<\/jats:italic>\n \u202f=\u202f190, ROR\u202f=\u202f1.46 (95% CI 1.26\u20131.68), IC\u202f=\u202f0.54 (IC025 0.32), Bonferroni-\n p<\/jats:italic>\n \u202f=\u202f0.0013], Sinus Headache [\n n<\/jats:italic>\n \u202f=\u202f65, ROR\u202f=\u202f2.38 (95% CI 1.86\u20133.04), IC\u202f=\u202f1.23 (IC025 0.84), Bonferroni-\n p<\/jats:italic>\n =\u202f1.0944e\n \u221208<\/jats:sup>\n ], and Carotid Artery Occlusion [\n n<\/jats:italic>\n \u202f=\u202f56, ROR\u202f=\u202f3.08 (95% CI 2.36\u20134.02), IC\u202f=\u202f1.59 (IC025 1.16), Bonferroni-\n p<\/jats:italic>\n =\u202f3.2089e\n \u221214<\/jats:sup>\n ]. Analysis of real-world follow-up data from Chinese CHD patients revealed that, compared to CHD patients not using any PCSK9 inhibitors, those treated with PCSK9 inhibitors exhibited significantly higher incidences of Memory Impairment (\n p<\/jats:italic>\n \u202f&lt;\u202f0.0001) and Head Discomfort (\n p<\/jats:italic>\n \u202f=\u202f0.0027).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Our study highlights that it is essential to recognize the potential risks of adverse neurological reactions, particularly Memory Impairment and Head Discomfort. These findings may assist healthcare professionals in providing more precise and individualized treatment plans.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2026.1765715","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:40:25Z","timestamp":1772779225000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrating pharmacovigilance signals with real-world validation: a study on neurological events associated with PCSK9 inhibitors"],"prefix":"10.3389","volume":"13","author":[{"given":"Bing","family":"Zhu","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Shao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cui","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyan","family":"Fu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Ma","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinjiang Medical University","place":["Urumqi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1016\/j.jacc.2018.11.004","article-title":"Systematic review for the 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the american college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Wilson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.3390\/cells11192972","article-title":"PCSK9 inhibition: from current advances to evolving future","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.33963\/KP.a2023.0030","article-title":"PCSK9 inhibitors and reduction in cardiovascular events: current evidence and future perspectives","volume":"81","author":"Nicholls","year":"2023","journal-title":"Kardiol Pol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.31083\/j.rcm2510374","article-title":"Rationale for early administration of PCSK9 inhibitors in acute coronary syndrome","volume":"25","author":"Sorrentino","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2023.01.001","article-title":"Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)","volume":"366","author":"Gargiulo","year":"2023","journal-title":"Atherosclerosis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2023.01.002","article-title":"Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: final results from the European observational HEYMANS study","volume":"366","author":"Ray","year":"2023","journal-title":"Atherosclerosis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e011382","DOI":"10.1161\/circinterventions.121.011382","article-title":"Effect of evolocumab in patients with prior percutaneous coronary intervention","volume":"15","author":"Furtado","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1536\/ihj.22-052","article-title":"Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome","volume":"63","author":"Hao","year":"2022","journal-title":"Int Heart J"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-023-01752-4","article-title":"Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease","volume":"22","author":"Nishikido","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1194\/jlr.R400004-JLR200","article-title":"Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal","volume":"45","author":"Dietschy","year":"2004","journal-title":"J Lipid Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"100426","DOI":"10.1016\/j.jlr.2023.100426","article-title":"PCSK9 and the nervous system: a no-brainer?","volume":"64","author":"Jaafar","year":"2023","journal-title":"J Lipid Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/cells14181479","article-title":"PCSK9 regulation of lipid metabolism in the nervous system: implications for Schwann cell function and peripheral neuropathy","volume":"14","author":"Nowacka","year":"2025","journal-title":"Cells"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/s41598-018-35232-7","article-title":"Lipoprotein markers associated with disability from multiple sclerosis","volume":"8","author":"Gafson","year":"2018","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"21020","DOI":"10.1038\/s41598-022-25180-8","article-title":"Association between serum lipid levels over time and risk of Parkinson\u2019s disease","volume":"12","author":"Hurh","year":"2022","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e1062","DOI":"10.1212\/wnl.0000000000201657","article-title":"Association between serum lipids and survival in patients with amyotrophic lateral sclerosis","volume":"100","author":"van Janse Mantgem","year":"2023","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1007\/s00018-012-0977-6","article-title":"PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling","volume":"69","author":"Kysenius","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"107652","DOI":"10.1016\/j.phrs.2025.107652","article-title":"Neuronal PCSK9 regulates cognitive performances via the modulation of ApoER2 synaptic localization","volume":"213","author":"Pelucchi","year":"2025","journal-title":"Pharmacol Res"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.bbrc.2008.04.004","article-title":"Secreted proprotein convertase subtilisin\/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo","volume":"370","author":"Schmidt","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.3390\/pharmaceutics15041268","article-title":"Endocrine regulation of microvascular receptor\u2014mediated Transcytosis and its therapeutic opportunities: insights by PCSK9\u2014mediated regulation","volume":"15","author":"Mazura","year":"2023","journal-title":"Pharmaceutics"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.cca.2018.04.040","article-title":"PCSK9: a potential regulator of apoE\/apoER2 against inflammation in atherosclerosis?","volume":"483","author":"Bai","year":"2018","journal-title":"Clin Chim Acta"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1021\/acs.biochem.0c00741","article-title":"An allosteric binding site on Sortilin regulates the trafficking of VLDL, PCSK9, and LDLR in hepatocytes","volume":"59","author":"Sparks","year":"2020","journal-title":"Biochemistry"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1084633","DOI":"10.3389\/fnmol.2022.1084633","article-title":"PCSK9 deficiency alters brain lipid composition without affecting brain development and function","volume":"15","author":"P\u00e4rn","year":"2023","journal-title":"Front Mol Neurosci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1017\/s1740925x09990184","article-title":"Reelin and apoE actions on signal transduction, synaptic function and memory formation","volume":"4","author":"Rogers","year":"2009","journal-title":"Neuron Glia Biol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/nn1426","article-title":"High cholesterol level is essential for myelin membrane growth","volume":"8","author":"Saher","year":"2005","journal-title":"Nat Neurosci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1194\/jlr.R009761","article-title":"Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models","volume":"52","author":"Chrast","year":"2011","journal-title":"J Lipid Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10545-012-9509-7","article-title":"Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases","volume":"36","author":"Lamari","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"eadi5571","DOI":"10.1126\/sciadv.adi5571","article-title":"Human cerebrospinal fluid contains diverse lipoprotein subspecies enriched in proteins implicated in central nervous system health","volume":"9","author":"Merrill","year":"2023","journal-title":"Sci Adv"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/biomedicines9070793","article-title":"PCSK9: a multi-faceted protein that is involved in cardiovascular biology","volume":"9","author":"Sundararaman","year":"2021","journal-title":"Biomedicine"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1186\/s40001-025-02937-1","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach","volume":"30","author":"Zheng","year":"2025","journal-title":"Eur J Med Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"100360","DOI":"10.1016\/j.xinn.2022.100360","article-title":"Myelin lipid metabolism and its role in myelination and myelin maintenance","volume":"4","author":"Barnes-V\u00e9lez","year":"2023","journal-title":"Int J Hydrogen Energ"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12974-025-03490-8","article-title":"Cholesterol in the CNS: functions, recycling and remyelination","volume":"22","author":"Wuerch","year":"2025","journal-title":"J Neuroinflammation"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s13238-014-0131-3","article-title":"Cholesterol metabolism and homeostasis in the brain","volume":"6","author":"Zhang","year":"2015","journal-title":"Protein Cell"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"10128","DOI":"10.1523\/jneurosci.0884-11.2011","article-title":"Schwann cell mitochondrial metabolism supports long-term axonal survival and peripheral nerve function","volume":"31","author":"Viader","year":"2011","journal-title":"J Neurosci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3109\/00207454.2015.1057636","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke","volume":"126","author":"Zhang","year":"2016","journal-title":"Int J Neurosci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1038\/s41467-024-46336-2","article-title":"PCSK9 stimulates Syk, PKC\u03b4, and NF-\u03baB, leading to atherosclerosis progression independently of LDL receptor","volume":"15","author":"Shin","year":"2024","journal-title":"Nat Commun"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"111195","DOI":"10.1016\/j.intimp.2023.111195","article-title":"PCSK9 inhibitor protects against ischemic cerebral injury by attenuating inflammation via the GPNMB\/CD44 pathway","volume":"126","author":"Zheng","year":"2024","journal-title":"Int Immunopharmacol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1765715\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:40:27Z","timestamp":1772779227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1765715\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":39,"alternative-id":["10.3389\/fmed.2026.1765715"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1765715","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]},"article-number":"1765715"}}